Laurion Capital Management LP Invests $950,000 in Illumina, Inc. (NASDAQ:ILMN)

Laurion Capital Management LP bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,112 shares of the life sciences company's stock, valued at approximately $950,000.

Several other large investors have also made changes to their positions in ILMN. Capital World Investors boosted its position in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after acquiring an additional 14,481,232 shares in the last quarter. Brown Advisory Inc. boosted its position in Illumina by 54,220.9% in the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after buying an additional 1,909,118 shares in the last quarter. Norges Bank acquired a new stake in Illumina in the fourth quarter valued at approximately $228,714,000. Bessemer Group Inc. boosted its position in Illumina by 32,837.5% in the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after buying an additional 1,344,038 shares in the last quarter. Finally, WCM Investment Management LLC boosted its position in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after buying an additional 867,673 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Insider Buying and Selling at Illumina

In related news, CFO Ankur Dhingra purchased 6,100 shares of the firm's stock in a transaction on Monday, May 12th. The stock was purchased at an average cost of $81.21 per share, with a total value of $495,381.00. Following the completion of the purchase, the chief financial officer now owns 24,906 shares in the company, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.17% of the company's stock.

Illumina Trading Up 3.4%

NASDAQ ILMN traded up $2.72 during mid-day trading on Friday, reaching $83.62. 2,338,618 shares of the stock were exchanged, compared to its average volume of 2,316,765. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The stock has a 50 day simple moving average of $78.48 and a 200-day simple moving average of $111.12. The stock has a market cap of $13.23 billion, a P/E ratio of -10.89, a P/E/G ratio of 1.60 and a beta of 1.35. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter last year, the firm earned $0.98 earnings per share. Illumina's quarterly revenue was down 1.4% on a year-over-year basis. On average, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ILMN. TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and cut their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Robert W. Baird cut their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Hsbc Global Res lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Royal Bank of Canada cut their target price on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 8th. Finally, Barclays cut their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $130.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.